Aethlon Medical (AEMD) closed at $5.05 on October 23, 2026, down 2.7% from the previous close, on volume of 45,396 shares (30-day average 3,290,135).
Data as of October 23, 2026.
Market Chameleon (Tue, 22-Sep 7:42 AM ET)
Are PRTH, MG, AEMD Obtaining Fair Deals for their Shareholders?
PRNewswire (Mon, 21-Sep 2:31 PM ET)
PRNewswire (Fri, 18-Sep 2:00 PM ET)
AEMD deal spotlight: law firm probes whether North Immunology merger terms are fair
Market Chameleon (Fri, 18-Sep 5:58 AM ET)
Globe Newswire (Thu, 17-Sep 3:27 PM ET)
Four High-Impact Small Caps Enter the Spotlight
Globe Newswire (Thu, 17-Sep 11:37 AM ET)
Business Wire (Thu, 17-Sep 8:24 AM ET)
Market Chameleon (Thu, 17-Sep 3:05 AM ET)
PRNewswire (Thu, 17-Sep 6:31 AM ET)
Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live stream
Globe Newswire (Wed, 19-Aug 7:00 AM ET)
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
Aethlon Medical trades on the NASDAQ stock market under the symbol AEMD.
As of October 23, 2026, AEMD stock price declined to $5.05 with 45,396 million shares trading.
AEMD has a beta of 5.48, meaning it tends to be more sensitive to market movements. AEMD has a correlation of 0.08 to the broad based SPY ETF.
AEMD has a market cap of $3.59 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, AEMD traded as high as $187.99 and as low as $.53.
AEMD has underperformed the market in the last year with a price return of +4.1% while the SPY ETF gained +14.9%. However, in the short term, AEMD had mixed performance relative to the market. It has outperformed in the last 3 months, returning +752.8% vs +1.9% return in SPY. But in the last 2 weeks, AEMD shares have been beat by the market, returning -16.0% compared to an SPY return of -1.8%.
AEMD support price is $4.94 and resistance is $5.44 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AEMD shares will trade within this expected range on the day.